Gout in Allopurinol Allergy or Intolerance — Next Step When Acute Flare Treatment Has Not Achieved Resolution
Clinical Scenario
This protocol applies to patients with gout who have a documented allergy to or intolerance of allopurinol, the standard first-line urate-lowering agent, and who therefore require an alternative approach to long-term urate management.
Previous Treatment — Failure Condition
Prior line
Acute gout flare treatment with colchicine, naproxen, indomethacin, prednisolone, or corticosteroid injections did not achieve resolution of the acute flare with relief of joint pain and inflammation. This unmet goal drives escalation to the present management protocol.
Treatment Approach (Partial Overview)
The protocol centres on urate-lowering therapy from an alternative drug class, combined with a defined prophylactic strategy during the initiation period and structured lifestyle guidance — the complete regimen is available in the full protocol.
Clinical Targets
Serum uric acid <6 mg/dL (360 mmol/L), maintained lifelong. In patients with severe gout, a stricter target of <5 mg/dL (300 mmol/L) is pursued until total crystal dissolution is confirmed.
References
DOI: 10.1136/annrheumdis-2016-209707
- Febuxostat or a uricosuric are also indicated if allopurinol cannot be tolerated.
- If the SUA target cannot be reached by an appropriate dose of allopurinol, allopurinol should be switched to febuxostat or a uricosuric, or combined with a uricosuric.
- Prophylaxis is recommended during the first 6 months of ULT.
- Every person with gout should receive advice regarding lifestyle: weight loss if appropriate and avoidance of alcohol (especially beer and spirits) and sugar-sweetened drinks, heavy meals and excessive intake of meat and seafood.
- Low-fat dairy products should be encouraged.
- Regular exercise should be advised.
- For patients on ULT, SUA level should be monitored and maintained to <6 mg/dL (360 mmol/L).
- A lower SUA target (<5 mg/dL; 300 mmol/L) to facilitate faster dissolution of crystals is recommended for patients with severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution and resolution of gout.
- SUA <6 mg/dL (360 mmol/L) should be maintained lifelong.
View source ↗